NovaBridge (NBP) announced enrollment of the first patient in the global Phase 2 randomized combination study evaluating givastomig, a Claudin 18.2 x 4-1BB bispecific antibody, in combination with nivolumab and chemotherapy in patients with HER2-negative, 1L metastatic gastric cancer.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBP:
- NovaBridge Doses First Patient in Global Phase 2 Gastric Cancer Trial of Givastomig
- Amazon downgraded, Roblox upgraded: Wall Street’s top analyst calls
- NovaBridge Biosciences Unveils February 2026 Investor Presentation Highlighting Global Hub-and-Spoke Biotech Strategy
- Reaffirming Buy on NovaBridge Biosciences: Differentiated Givastomig Profile, Expanded Patient Reach, and Strengthened Long-Term Value Proposition
- NovaBridge resumed with a Buy at H.C. Wainwright